The etiology of Parkinson's disease (PD) is not well understood but likely to involve both
genetic and environmental factors. Incidence and prevalence estimates vary to a large …

Parkinson's disease (PD) is the second most frequent neurodegenerative brain disease
(NBD) after Alzheimer's disease (AD). Statins are the most common lipid‐lowering agents …

Objective To prospectively examine whether use of statins is associated with altered risk of
Parkinson disease (PD). Design, Setting, and Participants A prospective study including 38 …

The burden of Parkinson's disease (PD) is likely to increase in the years to come as many
countries, particularly those in Asia, face an ageing population. As such, it has been …

Parkinson's disease (PD) is a neurodegenerative disorder marked by the selective
degeneration of dopaminergic neurons in the nigrostriatal pathway. Several lines of …

The field of the potential applications of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)
reductase inhibitors (statins) beyond their unambiguous cardiovascular beneficial effects is …

Affective disorders and memory impairments precede the classical motor symptoms seen in
Parkinson's disease (PD) and the currently approved antiparkinsonian agents do not …

Inconsistent results regarding the association between statin use and risk of Parkinson's
disease (PD) have been reported. We therefore examined the association between statin …

Neurodegenerative disorders which affects a larger population pose a great clinical
challenge. These disorders impact the quality of life of an individual by damaging the …

The accumulation of aggregated forms of the α-synuclein (αSN) is associated with the
pathogenesis of Parkinson's disease (PD) and Dementia with Lewy Bodies. The loss of …